BioPharma Credit PLC entered into an amendment to the credit facility with JPMorgan Chase Bank. Key terms to the amendment include: Reduction in the committed Revolving Credit Facility from USD 200 million to USD 50 million together with changes in the accordion feature allowing for an increase in the RCF to USD 100 million and up to USD 200 million in term loans; Extension of the maturity date to June 22, 2024; A reduction in the margin payable under the RCF from 4.00% to 2.75% According to its Articles of Association, the Company may incur indebtedness of up to a maximum of 50 per cent. of its net asset value, calculated at the time of drawdown, for investment and for working capital purposes. Pharmakon Advisors, LP, the Company's Investment Manager, has agreed not to incur aggregate borrowings greater than 25 per cent. of the Company's net asset value, calculated at the time of drawdown, without prior Board approval.